Evidence map›Paper›PMID 42294271›Full record

ArticleFrontiers in oncology2026

Synergistic anticancer effect of ellagic acid and Kaempferol combination in a mouse model of breast cancer.

Rand Jabbar Shihab, Moudi M Alasmari, Heba K Alshaeri, Márta Hock, Wamidh H Talib, Sergej Ostojic

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Potent Therapeutic Insights FromFood science & nutrition · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rand Jabbar ShihabDepartment of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Applied Science Private University, Amman, Jordan.
Moudi M AlasmariCollege of Medicine, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), Jeddah, Saudi Arabia.
Heba K AlshaeriDepartment of Pharmacology, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia.
Márta HockInstitute of Physiotherapy and Sports Science, Faculty of Health Sciences, University of Pécs, Pécs, Hungary.
Wamidh H TalibFaculty of Allied Medical Sciences, Applied Science Private University, Amman, Jordan.
Sergej OstojicInstitute of Physiotherapy and Sports Science, Faculty of Health Sciences, University of Pécs, Pécs, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cancer continues to be a major global health issue and is one of the leading causes of death. Breast cancer ranks among the most common neoplasms worldwide. Natural products have shown notable advantages in cancer treatment. Ellagic acid (EA), a polyphenolic compound found in natural sources, has potent anticancer properties. Kaempferol (KAE) is a natural substance known for its strong anticancer activity. This study investigated the antitumor activity of the combined use of EA and KAE on various cancer cell lines. Methods: Results: Conclusion: The combination of EA and KAE represents a promising candidate for breast cancer treatment due to its synergistic effect. It maximizes therapeutic potential through the induction of apoptosis.

Indexed as

anticancer therapiesbreast cancercombination treatmentellagic acidKaempferol

Identifiers

PMID42294271
PMCPMC13253396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.